INSMED INC (INSM)
US4576693075 - Common Stock
Overall INSM gets a fundamental rating of 2 out of 10. We evaluated INSM against 577 industry peers in the Biotechnology industry. INSM may be in some trouble as it scores bad on both profitability and health. INSM is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year INSM has reported negative net income.
In the past year INSM has reported a negative cash flow from operations.
INSM had negative earnings in each of the past 5 years.
INSM had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
INSM's Return On Assets of -64.44% is on the low side compared to the rest of the industry. INSM is outperformed by 63.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.44% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-40.13%
ROA(5y)-38.32%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
INSM's Gross Margin of 78.07% is amongst the best of the industry. INSM outperforms 86.41% of its industry peers.
In the last couple of years the Gross Margin of INSM has remained more or less at the same level.
INSM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 78.07% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.21%
GM growth 5Y0.78%
2. Health
2.1 Basic Checks
INSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, INSM has more shares outstanding
INSM has more shares outstanding than it did 5 years ago.
INSM has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -1.18, we must say that INSM is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.18, INSM perfoms like the industry average, outperforming 54.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.18 |
ROIC/WACCN/A
WACC10.42%
2.3 Liquidity
INSM has a Current Ratio of 1.80. This is a normal value and indicates that INSM is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.80, INSM is not doing good in the industry: 78.22% of the companies in the same industry are doing better.
INSM has a Quick Ratio of 1.61. This is a normal value and indicates that INSM is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of INSM (1.61) is worse than 79.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.61 |
3. Growth
3.1 Past
INSM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -22.48%.
Looking at the last year, INSM shows a very strong growth in Revenue. The Revenue has grown by 22.54%.
INSM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.92% yearly.
EPS 1Y (TTM)-22.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.4%
Revenue 1Y (TTM)22.54%
Revenue growth 3Y22.9%
Revenue growth 5Y98.92%
Sales Q2Q%15.77%
3.2 Future
The Earnings Per Share is expected to grow by 19.93% on average over the next years. This is quite good.
The Revenue is expected to grow by 48.26% on average over the next years. This is a very strong growth
EPS Next Y13.88%
EPS Next 2Y11.9%
EPS Next 3Y16.48%
EPS Next 5Y19.93%
Revenue Next Year16.4%
Revenue Next 2Y30%
Revenue Next 3Y44.08%
Revenue Next 5Y48.26%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for INSM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INSM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as INSM's earnings are expected to grow with 16.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.9%
EPS Next 3Y16.48%
5. Dividend
5.1 Amount
No dividends for INSM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INSMED INC
NASDAQ:INSM (7/26/2024, 7:00:02 PM)
After market: 74.54 0 (0%)74.54
+0.04 (+0.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap12.16B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.44% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 78.07% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.61 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-22.48%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y13.88%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)22.54%
Revenue growth 3Y22.9%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y